Related Experiment Video
Updated: Aug 5, 2026
Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis
Published on: January 7, 2019
GRPR-Targeted Radionuclide Conjugates: A Molecular Evolution Perspective
Meng Li1,2,3, Yu Liu4, MengChao Cui3
1HTA Co., Ltd, Beijing, China.
Abstract:
The gastrin-releasing peptide receptor (GRPR) serves as an important target for radiopharmaceutical conjugates in cancer diagnosis and therapy. This article systematically reviewed the evolution of GRPR-targeted ligands: from early agonists whose clinical application was limited by side effects, to current antagonists with improved stability and tumor retention. Key structural optimizations include C-terminal modifications of peptides, along with the design of linkers and chelators, which collectively enhance targeting capability and pharmacokinetic properties. Despite the significant progress achieved so far, challenges such as off-target uptake and inadequate metabolic stability still remain. Future research should be directed toward elucidating structure-activity relationships and designing novel ligands, linkers and chelators to promote the development of more selective and efficient diagnostic and therapeutic radiopharmaceuticals for cancers with high GRPR expression.
Insights
Gastrin-releasing peptide receptor (GRPR) targeted radiopharmaceuticals are advancing for cancer care. Ligand design improvements enhance tumor targeting, but challenges in stability and specificity remain for future development.
Area of Science:
- Oncology
- Radiopharmaceutical Science
- Medicinal Chemistry
Background:
- The gastrin-releasing peptide receptor (GRPR) is a key target for developing targeted radiopharmaceuticals for cancer diagnosis and therapy.
- Early GRPR-targeted agonists faced limitations due to side effects and poor clinical applicability.
Purpose of the Study:
- To systematically review the evolution of GRPR-targeted ligands.
- To highlight structural optimizations and their impact on targeting capability and pharmacokinetics.
- To identify remaining challenges and future research directions in GRPR-targeted radiopharmaceuticals.
Main Methods:
- Systematic literature review focusing on the development of GRPR-targeted ligands.
- Analysis of structural modifications in peptide-based ligands, including C-terminal changes.
- Evaluation of linker and chelator designs for enhancing radiopharmaceutical properties.
Main Results:
- GRPR antagonists show improved stability and tumor retention compared to earlier agonists.
- Structural optimizations, including C-terminal modifications and advanced linker/chelator designs, enhance targeting and pharmacokinetics.
- Despite progress, challenges persist regarding off-target uptake and metabolic stability of current ligands.
Conclusions:
- Significant advancements have been made in GRPR-targeted ligand design for cancer radiopharmaceuticals.
- Further research is needed to overcome limitations such as off-target uptake and metabolic instability.
- Future efforts should focus on structure-activity relationships and novel designs for more selective and effective diagnostic and therapeutic agents for GRPR-expressing cancers.
